Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

Targacept Company Profile - Aug 05, 2011

VIEWS: 22 PAGES: 9

Targacept, Inc. is a biopharmaceutical company engaged in the design, discovery and development of neuronal nicotinic receptor (NNR) Therapeutics for the treatment of diseases and disorders of the nervous system. The Company's NNR Therapeutics target NNRs. As of December 31, 2010, it had a number of clinical-stage product candidates and preclinical programs. The Company has two collaborations with the pharmaceutical company, AstraZeneca, one a collaboration and license agreement focused on TC-5214, as a treatment for depressive disorder, and the other is a collaborative research and license agreement focused in cognitive disorders. As of December 31, 2010, the Company's advanced product candidates included TC-5214, TC-5619, AZD3480 (TC-1734), AZD1446, TC-6987, TC-6499 and Pentad.

More Info
									Company Fundamentals\Company Profile

   A Wright Investors' Service Research Report:

   Targacept, Inc.
                                                                                          440 Wheelers Farms Road
                                                                                          Milford, CT 06461 U.S.A.


  COMPANY PROFILE
  Figures in U.S. Dollars

                                 Wright Quality Rating:CANN                                 Key Data

   Targacept, Inc. is a biopharmaceutical company engaged in the design, discovery          Ticker:
   and development of NNR Therapeutics for the treatment of diseases and disorders of       TRGT
   the central nervous system. Its NNR Therapeutics focuses on neuronal nicotinic
   receptors (NNRs). The Company has a range of clinical-stage product candidates           2010 Sales:
   and preclinical programs, which includes TC-5214, AZD3480 (TC-1734) and AZD1446
                                                                                            85,713,000
   (TC-6683), TC-5619, TC-6987, TC-6499 and TC-5685. The Company has preclinical
   research programs in smoking cessation, addiction, obesity, pain and Parkinson's
   disease. In addition, it has a program focused on the role of NNRs in inflammation       Major Industry:
   involving the affecting of cytokines. The Company also has two collaborations with       Drugs, Cosmetics & Health
   AstraZeneca, one focused on TC-5214 as a treatment for depressive disorder and           Care
   one focused in cognitive disorders, as well as an alliance with GlaxoSmithKline.
                       Stock Chart                                    Officers              Sub Industry:
                                                                     Chairman               Ethical Drug Manufacturers
                                                                Dr. Mark B. Skaletsky
                                                                                            Country:
                                                         President & Chief Executive        United States
                                                            Dr. J. Donald deBethizy
                                                                                            Currency:
                                                                Senior Vice President       U.S. Dollars
                                                              Finance, Chief Financial
                                                                 Officer & Treasurer
                                                                                            Fiscal Year Ends:
                                                                     Alan A. Musso
                                                                                            December
                                                              Vice President Finance
                                                                  Mauri K. Hodges           Employees
                                                                                            132
                                                           Senior Vice President,
                                                        Secretary & General Counsel Exchanges:
                                                              Peter A. Zorn Esq.    NAS

                                                                                            Share Type:
                                                                                            Common
            Stock Price (7/29/2011): 20.44
               Recent stock performance
                                                                                            Market 
								
To top